LCN2 and cancer: Targeting NGAL in advanced thyroid tumors is a valuable therapeutic option that could open new perspectives for the treatment of these uncurable malignancies, especially if one considers that a number of NGAL inhibitors have already been tested in different human cancers and that others are currently under investigation [92].